Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

VRBPAC recommends expanding EUAs to authorize Janssen and Moderna boosters

By Brian Buntz | October 15, 2021

COVID-19 vaccine

Image from Sam Moqadam on Unsplash

The U.S. appears to be on the verge of expanding the use of COVID-19 vaccine boosters after an advisory committee backed boosters for the Johnson & Johnson (NYSE:JNJ) and Moderna (NSDQ:MRNA) vaccines.

On Oct. 14 and 15, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) separately voted 19–0 to recommend boosters of both products.

VRBPAC recommended that recipients of the single-dose Janssen vaccine receive a booster at least two months after the initial dose.

The committee’s guidance for the two-dose mRNA vaccines from Moderna and Pfizer-BioNTech (NYSE: PFE/NSDQ:BNTX) was to allow boosters six months after completion of a primary series.

Several panelists balked at the word “booster” in reference to the Janssen vaccine, arguing that would be more accurate to start referring to it as a two-dose vaccine. The Janssen’s Ad26.COV2.S was “always a two-dose vaccine and it’s hard to recommend it as a single-dose vaccine,” said VRBPAC member Dr. Paul Offit.

VRBPAC member Dr. Archana Chatterjee said she had a similar perspective, but added “there’s so much confusion around these vaccines anyway that I thought introducing another term [‘additional dose’ versus ‘booster’] might be even more confusing.”

The VRBPAC has expressed reservations about the use of boosters in the broader public. Although members of the committee agreed the case for boosters was clear for the elderly, immunocompromised and those facing a high risk of occupational or institutional exposure, the panel was overall frustrated with the availability of relevant data concerning boosters.

Committee members were, however, more supportive of the use of a second dose of the Janssen vaccine, given a single dose of the vaccine does not tend to stimulate antibodies as well as two doses of the mRNA vaccines.

Chatterjee expressed skepticism that boosters would move the needle in fighting the pandemic, noting that the U.S. is “seeing cases going down”  without boosters. There may be little present need for boosters for those who are immune competent, she said.

“The disease primarily seems to be occurring, especially in its most severe forms, in those who are unvaccinated,” Chatterjee said in yesterday’s meeting.

Offit agreed. “The people who are in the ICU aren’t there because they haven’t gotten the third dose,” he said.

“I just worry that we haven’t clearly defined what the goal of this vaccine is,” Offit continued. “If the goal of the [COVID-19] vaccine is to prevent asymptomatic or mildly symptomatic infection, that is a goal for which we have set for no other vaccine,” he explained. “If we’re trying to prevent what is inevitable, which is the decline in neutralizing antibodies, and erosion of protection against mild or asymptomatic infection, that is a high bar to which we hold no other vaccine.”


Filed Under: Infectious Disease
Tagged With: booster, COVID-19 vaccine, COVID-19 vaccines, Janssen, Moderna, vaccine, Vaccines and Related Biological Products Advisory Committee, VRBPAC
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Pfizer-BioNTech
FDA allows booster dose Pfizer-BioNTech COVID-19 vaccine in children 5 to 11
AstraZeneca RQ Biotechnology
AstraZeneca paying up to $157M for broad-spectrum monoclonal antibodies against COVID
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative
Olumiant
FDA approves Olumiant for treating some hospitalized COVID-19 patients

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50